Free tool
Drug Trial Radar: Hematology and blood cancers
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
74
Not yet recruiting, industry sponsors, Hematology and blood cancers, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting286
- Completed1,361
74 trials
Showing 1 to 25, recently updated first.
- A Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune ThrombocytopeniaNot yet recruiting
CASI pharmaceuticals, Inc.Industry
NCT07946549 · 54 participants (planned) · Start Nov 30, 2026 · Primary completion Nov 30, 2028
Drug: CID-103 · For: Chronic Immune Thrombocytopenia
Sites: Beijing, China; Guangzhou, China; Tangshan, China · 11 sites in all
- S243249 Monotherapy in Patients With Relapsed or Refractory Acute Leukemia With a KMT2A or NUP98 Translocation or Relapsed or Refractory AML With NPM1c MutationNot yet recruiting
ServierIndustry
NCT07722312 · 80 participants (planned) · Start Feb 1, 2027 · Primary completion Aug 11, 2029
Drug: S243249 600mg; S243249 400mg and 2 more · For: Relapsed or Refractory Acute Leukemia; Relapsed or Refractory Acute Myeloid Leukemia
- A Study of TBS-2025 Monotherapy in Participants With r/r NPM1mut AMLNot yet recruiting
TuHURA Biosciences, Inc.Industry
NCT07939971 · 55 participants (planned) · Start Dec 2026 · Primary completion Dec 2028
Drug: TBS-2025 · For: Acute Myeloid Leukemia
- A Study to Evaluate Ofirnoflast in Adults With Very Low- to Intermediate-risk Myelodysplastic Syndromes Requiring Red Blood Cell TransfusionsNot yet recruiting
Halia Therapeutics, Inc.Industry
NCT07738510 · 70 participants (planned) · Start Nov 2026 · Primary completion Oct 2028
Drug: Ofirnoflast · For: Myelodysplastic Syndromes; Anemia
Sites: Cleveland, Ohio
- Study of YKST02 in Adults With Relapsed or Refractory Multiple MyelomaNot yet recruiting
Excyte Biopharma LtdIndustry
NCT07695740 · 64 participants (planned) · Start Dec 2027 · Primary completion Dec 2030
Drug: YKST02 · For: Relapsed or Refractory Multiple Myeloma (RRMM)
Sites: Beijing, China
- A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010)Pivotal-lookingNot yet recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07917754 · 470 participants (planned) · Start Dec 13, 2026 · Primary completion Mar 13, 2037
Drug: MK-1045; Zilovertamab vedotin and 8 more · For: Lymphoma, Large B-Cell, Diffuse; Diffuse Large B-Cell Lymphoma
- A Study of MBS314 for Injection in Participants With Relapsed/Refractory Multiple Myeloma.Not yet recruiting
Beijing Mabworks Biotech Co., Ltd.Industry
NCT07911748 · 78 participants (planned) · Start Nov 2026 · Primary completion Dec 2027
Drug: MBS314 for Injection · For: Multiple Myeloma
- A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid TumorsNot yet recruiting
Medsyn Biopharma, LLCIndustry
NCT07899632 · 75 participants (planned) · Start Nov 2026 · Primary completion Aug 2029
Drug: MDSY-1240 · For: Triple-Negative Breast Cancer (TNBC); Gastric Cancer (GC); Gastric Cancer Adenocarcinoma Metastatic and 11 more
- A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic LeukemiaNot yet recruiting
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT07770698 · 30 participants (planned) · Start Dec 2026 · Primary completion Apr 30, 2030
Drug: sonrotoclax; Azacitidine and 2 more · For: Relapsed Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia; B-cell Acute Lymphoblastic Leukemia and 9 more
- HEC53856 Tablets for Chemotherapy-induced Anemia in Non-myeloid MalignanciesPivotal-lookingNot yet recruiting
Sunshine Lake Pharma Co., Ltd.Industry
NCT07891377 · 160 participants (planned) · Start Dec 2026 · Primary completion Feb 2028
Drug: HEC53856 tablet; rHuEPO injection · For: Chemotherapy-induced Anemia; Non-Myeloid Malignancy
Sites: Shanghai, China
- REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs)Not yet recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07887750 · 36 participants (planned) · Start Dec 7, 2026 · Primary completion Nov 1, 2029
Drug: REGN9220; Odronextamab · For: Diffuse Large B-Cell Lymphoma (DLBCL)
- CK0801 for Treatment of Aplastic AnemiaNot yet recruiting
Cellenkos, Inc.Industry
NCT07499102 · 12 participants (planned) · Start Dec 3, 2026 · Primary completion Aug 3, 2028
Drug: CK0801 · For: Aplastic Anemia
- Flonoltinib Maleate Oral Regimens in Patients With MyelofibrosisPivotal-lookingNot yet recruiting
Chengdu Zenitar Biomedical Technology Co., LtdIndustry
NCT07750574 · 105 participants (planned) · Start Nov 2026 · Primary completion Nov 2028
Drug: Flonoltinib Maleate orally; Flonoltinib Maleate orally and 1 more · For: Myelofibrosis; Myelofibrosis Due to and Following Polycythemia Vera; Myelofibrosis Transformation in Essential Thrombocythemia and 9 more
- Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell TherapyNot yet recruiting
AbelZeta Inc.Industry
NCT07875413 · 55 participants (planned) · Start May 2027 · Primary completion Jun 2029
Drug: Prizloncabtagene Autoleucel · For: Large B Cell Lymphoma; LBCL; Diffuse Large B Cell Lymphoma (DLBCL) and 8 more
Sites: Gilbert, Arizona; La Jolla, California
- KATALYST-HEME-01: Study of the KAT6 Inhibitor MEN2312 in Heme MalignanciesPivotal-lookingNot yet recruiting
Stemline Therapeutics, Inc.Industry
NCT07873827 · 115 participants (planned) · Start Oct 30, 2026 · Primary completion May 12, 2028
Drug: MEN2312 · For: Hematological Malignancy
- A Phase II Study of TT-01488 Tablets in Combination With Anti-CD20 Monoclonal Antibody Therapy in Patients With Mantle Cell LymphomaNot yet recruiting
TransThera Sciences (Nanjing), Inc.Industry
NCT07855016 · 188 participants (planned) · Start Oct 10, 2026 · Primary completion Oct 10, 2029
Drug: TT-01488 Tablets; Rituximab and 2 more · For: Mantle Cell Lymphoma (MCL)
Sites: Guangzhou, China; Shanghai, China
- A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell LymphomaPivotal-lookingNot yet recruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT07818499 · 204 participants (planned) · Start Sep 2026 · Primary completion Dec 2028
Drug: BL-M08D1; Rituximab and 6 more · For: Diffuse Large B-Cell Lymphoma
Sites: Guangzhou, China; Suzhou, China
- SCTB35 and SCTB41 With or Without Chemotherapy in Non-Hodgkin LymphomaNot yet recruiting
Sinocelltech Ltd.Industry
NCT07819188 · 90 participants (planned) · Start Sep 30, 2026 · Primary completion Sep 30, 2028
Drug: SCTB35 injection; SCTB41 · For: NHL - Non-Hodgkin's Lymphoma
Sites: Tianjing, China
- A Study to Assess How Well the Study Medicine IPN60340 Works in Combination With Azacitidine and Venetoclax, Compared to Placebo in Combination With Azacitidine and Venetoclax, in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Cannot Receive Intensive ChemotherapyPivotal-lookingNot yet recruiting
IpsenIndustry
NCT07623187 · 540 participants (planned) · Start Nov 1, 2026 · Primary completion May 31, 2031
Drug: IPN60340 + azacitidine + venetoclax; Placebo + azacitidine + venetoclax · For: Acute Myeloid Leukaemia (AML); Acute Myeloid Leukaemia
- Study of SGB-9768 in Patients With Paroxysmal Nocturnal HemoglobinuriaNot yet recruiting
Suzhou Sanegene Bio Inc.Industry
NCT07796256 · 24 participants (planned) · Start Oct 31, 2026 · Primary completion Aug 31, 2027
Drug: SGB-9768 · For: PNH - Paroxysmal Nocturnal Hemoglobinuria
Sites: Tianjin, China; Hangzhou, China
- A Phase I/II Study of FG-M131 in TRBC1+ Relapsed/Refractory Peripheral T-Cell LymphomaNot yet recruiting
FutureGen Biopharmaceutical (Beijing) Co., LtdIndustry
NCT07758491 · 110 participants (planned) · Start Aug 30, 2026 · Primary completion Jan 2031
Drug: FG-M131; FG-M131 · For: PTCL; TRBC1 ADC; CTCL
Sites: Beijing, China
Kind Pharmaceuticals LLCIndustry
NCT06075030 · 36 participants (planned) · Start Dec 2027 · Primary completion Dec 2027
Drug: AND017 · For: Chemotherapy Induced Anemia
- A Study of AND017 to Treat Cancer Related Anemia in Patients Not Receiving ChemotherapyNot yet recruiting
Kind Pharmaceuticals LLCIndustry
NCT06075043 · 36 participants (planned) · Start Dec 2027 · Primary completion May 2028
Drug: AND017 · For: Cancer-Related Anemia
- A Study of BL-M11D1 in Patients With Relapsed/Refractory Myelodysplastic SyndromesNot yet recruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT07591168 · 92 participants (planned) · Start Sep 2026 · Primary completion Dec 2028
Drug: BL-M11D1 · For: Myelodysplastic Syndromes
Sites: Tianjin, China
- A Study of Avatrombopag in Adults With Aplastic Anemia Who Did Not Respond to, Cannot Receive, or Had Return of Disease After Standard TreatmentPivotal-lookingNot yet recruiting
Swedish Orphan BiovitrumIndustry
NCT07786922 · 26 participants (planned) · Start Jul 31, 2026 · Primary completion Jun 30, 2028
Drug: Avatrombopag 20 mg Oral Tablet · For: Aplastic Anemia
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.